1 Proportion of participants with pain response |
3 |
876 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.15 [0.93, 1.43] |
2 Skeletal‐related events: any |
9 |
3153 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.87 [0.81, 0.94] |
3 Skeletal‐related events: pathologic fracture |
6 |
2226 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.68 [0.53, 0.87] |
4 Skeletal‐related events: pathologic fractures: vertebral fracture |
2 |
993 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.84 [0.52, 1.36] |
5 Skeletal‐related events: pathologic fractures: non‐vertebral fracture |
2 |
993 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.76 [0.53, 1.10] |
6 Skeletal‐related events: spinal cord compression |
6 |
2226 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.67 [0.50, 0.89] |
7 Skeletal‐related events: bone radiation therapy |
6 |
1696 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.90 [0.77, 1.06] |
8 Skeletal‐related events: bone surgery |
5 |
1915 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.50 [0.29, 0.86] |
9 Mortality |
9 |
2450 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.97 [0.91, 1.04] |
10 Adverse events: nausea |
9 |
3008 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.19 [1.00, 1.41] |
11 Adverse events: renal |
7 |
1794 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.65 [1.11, 2.46] |
12 Adverse events: bone pain |
5 |
1445 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.93 [0.81, 1.06] |
13 Adverse events: osteonecrosis of the jaw |
5 |
1626 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.92 [0.75, 4.90] |
14 Proportion of participants with decreased analgesic consumption |
4 |
416 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.19 [0.87, 1.63] |
15 Proportion of participants with disease progression |
7 |
2115 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.94 [0.90, 0.98] |
16 Sensitivity analysis: pain response (low risk of bias vs high risk of bias) |
3 |
876 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.15 [0.93, 1.43] |
16.1 Low risk of bias |
1 |
227 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.23 [0.80, 1.89] |
16.2 High risk of bias |
2 |
649 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.13 [0.88, 1.44] |
17 Subgroup analysis: pain response (amino‐bisphosphonate vs non‐amino‐bisphosphonate) |
3 |
876 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.15 [0.93, 1.43] |
17.1 Amino‐bisphosphonate |
1 |
592 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.12 [0.87, 1.44] |
17.2 Non‐amino‐bisphosphonate |
2 |
284 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.23 [0.81, 1.87] |
18 Subgroup analysis: pain response (route of administration) |
3 |
876 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.15 [0.93, 1.43] |
18.1 Oral |
1 |
592 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.12 [0.87, 1.44] |
18.2 Intravenous |
2 |
284 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.23 [0.81, 1.87] |
19 Sensitivity analysis: skeletal‐related events (low risk of bias vs high risk of bias) |
9 |
3153 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.87 [0.81, 0.94] |
19.1 Low risk of bias |
5 |
1767 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.90 [0.81, 0.99] |
19.2 High risk of bias |
4 |
1386 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.84 [0.75, 0.94] |
20 Sensitivity analysis: skeletal‐related events (full‐text vs abstract publication) |
9 |
3153 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.87 [0.81, 0.94] |
20.1 Full‐text publication |
8 |
3093 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.88 [0.81, 0.95] |
20.2 Abstract publication |
1 |
60 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.40 [0.12, 1.37] |
21 Subgroup analysis: skeletal‐related events (amino‐bisphosphonate versus non‐amino‐bisphosphonate) |
9 |
3153 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.87 [0.81, 0.94] |
21.1 Amino‐bisphosphonate |
8 |
2842 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.86 [0.79, 0.94] |
21.2 Non‐amino‐bisphosphonate |
1 |
311 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.92 [0.78, 1.09] |
22 Subgroup analysis: skeletal‐related events (route of administration) |
9 |
3153 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.87 [0.81, 0.94] |
22.1 Oral |
2 |
374 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.92 [0.78, 1.09] |
22.2 Intravenous |
7 |
2779 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.86 [0.79, 0.94] |
23 Sensitivity analysis: mortality (low risk of bias vs high risk of bias)) |
9 |
2450 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.97 [0.91, 1.04] |
23.1 Low risk of bias |
6 |
1420 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.93 [0.85, 1.02] |
23.2 High risk of bias |
3 |
1030 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.04 [0.94, 1.15] |
24 Sensitivity analysis: mortality (full‐text vs abstract publication) |
9 |
2450 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.97 [0.91, 1.04] |
24.1 Full‐text publication |
8 |
2390 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.98 [0.91, 1.04] |
24.2 Abstract publication |
1 |
60 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.80 [0.32, 2.03] |
25 Subgroup analysis: mortality (amino‐bisphosphonate vs non‐amino‐bisphosphonate) |
9 |
2450 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.97 [0.91, 1.04] |
25.1 Amino‐bisphosphonate |
5 |
1738 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.98 [0.90, 1.07] |
25.2 Non‐amino‐bisphosphonate |
4 |
712 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.96 [0.87, 1.06] |
26 Subgroup analysis: mortality (route of administration) |
9 |
2450 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.97 [0.91, 1.04] |
26.1 Oral |
5 |
1140 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.02 [0.95, 1.11] |
26.2 Intravenous |
4 |
1310 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.91 [0.81, 1.02] |
27 Sensitivity analysis: adverse event: nausea (low risk of bias vs high risk of bias) |
9 |
3008 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.19 [1.00, 1.41] |
27.1 Low risk of bias |
7 |
2042 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.18 [0.99, 1.40] |
27.2 High risk of bias |
2 |
966 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.41 [0.49, 4.03] |
28 Subgroup analysis: adverse event: nausea (amino‐bisphosphonate vs non‐amino‐bisphosphonate) |
9 |
3008 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.19 [1.00, 1.41] |
28.1 Amino‐bisphosphonate |
5 |
2332 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.19 [0.98, 1.45] |
28.2 Non‐amino‐bisphosphonate |
4 |
676 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.18 [0.83, 1.68] |
29 Subgroup analysis: adverse event: nausea (route of administration) |
9 |
3008 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.19 [1.00, 1.41] |
29.1 Oral |
4 |
1059 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.15 [0.80, 1.67] |
29.2 Intravenous |
5 |
1949 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.20 [0.99, 1.45] |
30 Sensitivity analysis: renal (low risk of bias vs high risk of bias) |
7 |
1794 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.65 [1.11, 2.46] |
30.1 Low risk of bias |
5 |
1498 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.59 [1.06, 2.40] |
30.2 High risk of bias |
2 |
296 |
Risk Ratio (M‐H, Fixed, 95% CI) |
3.0 [0.48, 18.65] |
31 Subgroup analysis: renal (amino‐bisphosphonate vs non‐amino‐bisphosphonate) |
7 |
1794 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.65 [1.11, 2.46] |
31.1 Amino‐bisphosphonate |
5 |
1662 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.63 [1.09, 2.44] |
31.2 Non‐amino‐bisphosphonate |
2 |
132 |
Risk Ratio (M‐H, Fixed, 95% CI) |
3.24 [0.14, 77.15] |
32 Subgroup analysis: renal (route of administration) |
7 |
1794 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.65 [1.11, 2.46] |
32.1 Oral |
3 |
204 |
Risk Ratio (M‐H, Fixed, 95% CI) |
2.40 [0.37, 15.75] |
32.2 Intravenous |
4 |
1590 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.62 [1.07, 2.44] |